These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1009 related articles for article (PubMed ID: 20838997)

  • 1. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
    Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
    Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
    Chang H; Jeung HC; Jung JJ; Kim TS; Rha SY; Chung HC
    Breast Cancer Res Treat; 2011 Jan; 125(1):55-63. PubMed ID: 20224928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
    Knutson AK; Welsh J; Taylor T; Roy S; Wang WL; Tenniswood M
    Oncol Rep; 2012 Mar; 27(3):849-53. PubMed ID: 22159450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC; Parsons SJ
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
    Tong A; Zhang H; Li Z; Gou L; Wang Z; Wei H; Tang M; Liang S; Chen L; Huang C; Wei Y
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):791-802. PubMed ID: 17593366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
    Dietrich CS; Greenberg VL; DeSimone CP; Modesitt SC; van Nagell JR; Craven R; Zimmer SG
    Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
    Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
    Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
    Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.
    Yamamoto S; Tanaka K; Sakimura R; Okada T; Nakamura T; Li Y; Takasaki M; Nakabeppu Y; Iwamoto Y
    Anticancer Res; 2008; 28(3A):1585-91. PubMed ID: 18630516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.
    Shen J; Huang C; Jiang L; Gao F; Wang Z; Zhang Y; Bai J; Zhou H; Chen Q
    Biochem Pharmacol; 2007 Jun; 73(12):1901-9. PubMed ID: 17445779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis.
    Koyama M; Izutani Y; Goda AE; Matsui TA; Horinaka M; Tomosugi M; Fujiwara J; Nakamura Y; Wakada M; Yogosawa S; Sowa Y; Sakai T
    Clin Cancer Res; 2010 Apr; 16(8):2320-32. PubMed ID: 20371690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.